Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-A2-Ig fusion protein
- Development stage
- Preclinical
- Lead developer
- BD
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
HLA-A2-Ig fusion protein (often written HLA-A2:Ig) is a recombinant soluble dimeric fusion protein. It is widely utilized as a research-use-only (RUO) reagent, commercialized by BD Biosciences under the brand name BD DimerX, to detect, stain, and stimulate antigen-specific CD8+ T cells by binding to the T-cell receptor (TCR). The reagent consists of three extracellular MHC class I HLA-A2 domains fused to the VH regions of mouse IgG1, supplemented with recombinant β2-microglobulin (β2M) to facilitate peptide binding. Additionally, academic researchers at CHU Nice and CNRS have developed cytotoxic HLA-A2-Ig fusion protein variants (HLA-A2-Ig dimers) as potential therapeutic candidates for desensitization in highly sensitized transplant patients, designed to selectively target and deplete anti-HLA-A2 memory B cells and antibody-producing hybridomas via their B-cell receptors (BCR).
- Brand names
- BD DimerXDimerX
- Other names
- HLA-A2-IgHLA-A-2-IgHLA-A 2-IgHLA-A2-Ig dimerHLA-A-2-Ig dimerHLA-A 2-Ig dimerHLA-A2:IgHLA-A2:Ig fusion proteinHLA-A2:Ig recombinant soluble dimeric fusion protein
02
Targets
BCR (Immunoglobulin G B Cell Receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on HLA-A2-Ig fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-A2-Ig fusion protein.